Advertisement

LC-MS/MS Analysis of the Epoxides and Diols Derived from the Endocannabinoid Arachidonoyl Ethanolamide

  • Amy A. Rand
  • Patrick O. Helmer
  • Bora Inceoglu
  • Bruce D. Hammock
  • Christophe MorisseauEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1730)

Abstract

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a useful tool to characterize the behavior of natural lipids within biological matrices. We report a LC-MS/MS method developed specifically to analyze CYP products of the arachidonoyl ethanolamide (anandamide, AEA), the epoxyeicosatrienoic acid ethanolamides (EET-EAs) and their hydrolyzed metabolites, and the dihydroxyeicosatrienoic acid ethanolamides (DHET-EAs). This method was used to measure EET-EA biotransformation to DHET-EAs by two human epoxide hydrolases: the soluble EH (sEH) and the microsomal EH (mEH). In general, sEH and mEH substrate preference was similar, based on kcat/KM. The 14,15-EET-EA and 11,12-EET-EA were the most efficiently hydrolyzed, followed by 8,9-EET-EA and 5,6-EET-EA. The method was also used to detect endogenous levels of these lipids in mouse tissues, although levels were below the instrumental detection limit (0.1–3.4 nM). Because both AEA and EETs are biologically active, the method described herein will be invaluable in revealing the role(s) of EET-EAs in vivo.

Key words

Liquid chromatography mass spectrometry Anandamide CYP450 Epoxide hydrolase EET-EAs DHET-EAs Limit of -detection Enzyme kinetics Bioactivity 

Notes

Acknowledgments

This work received support in part from the National Institute of Environmental Health Sciences R01 ES002710 and NIEHS Superfund Program P42 ES004699. A. Rand acknowledges support from the OSCB training grant NIH/NIEHS T32 CA108459 and from the 2016 AACR Judah Folkman Fellowship for Angiogenesis Research, Grant Number 16-40-18-RAND.

References

  1. 1.
    Mechoulam R, Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21–47CrossRefPubMedGoogle Scholar
  2. 2.
    Snider NT, Walker VJ, Hollenberg PF (2010) Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. Pharmacol Rev 62:136–154CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Sridar C, Snider NT, Hollenberg PF (2011) Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos 39:782–788CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    McDougle DR, Kambalyal A, Meling DD, Das A (2014) Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase. J Pharmacol Exp Ther 351:616–627CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bornheim LM, Kim KY, Chen B, Correia MA (1995) Microsomal cytochrome P450-mediated liver and brain anandamide metabolism. Biochem Pharmacol 50:677–686CrossRefPubMedGoogle Scholar
  6. 6.
    Snider NT, Kornilov AM, Kent UM, Hollenberg PF (2007) Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther 321:590–597CrossRefPubMedGoogle Scholar
  7. 7.
    Zelasko S, Arnold WR, Das A (2015) Endocannabinoid metabolism by cytochrome P450 monooxygenases. Prostaglandins Other Lipid Mediat 116:112–123CrossRefPubMedGoogle Scholar
  8. 8.
    Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8:794–805CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Morisseau C, Hammock BD (2013) Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol 53:37–58. https://doi.org/10.1146/annurev-pharmtox-011112-140244CrossRefPubMedGoogle Scholar
  10. 10.
    Snider NT, Nast JA, Tesmer LA, Hollenberg PF (2009) A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. Mol Pharmacol 75:965–972CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bellien J, Joannides R (2013) Epoxyeicosatrienoic acid pathway in human health and diseases. J Cardiovasc Pharmacol 61:188–196CrossRefPubMedGoogle Scholar
  12. 12.
    Wagner K, Inceoglu B, Hammock BD (2011) Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. Prostaglandins Other Lipid Mediat 96:76–83CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Argiriadi MA, Morisseau C, Hammock BD, Christianson DW (1999) Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase. Proc Natl Acad Sci 96:10637–10642CrossRefPubMedGoogle Scholar
  14. 14.
    Morisseau C, Bernay M, Escaich A et al (2011) Development of fluorescent substrates for microsomal epoxide hydrolase and application to inhibition studies. Anal Biochem 414:154–162CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Morisseau C, Wecksler AT, Deng C et al (2014) Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation. J Lipid Res 55:1131–1138CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yang J, Schmelzer K, Georgi K, Hammock BD (2009) Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 81:80–85CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  • Amy A. Rand
    • 1
  • Patrick O. Helmer
    • 2
  • Bora Inceoglu
    • 1
  • Bruce D. Hammock
    • 1
  • Christophe Morisseau
    • 1
    Email author
  1. 1.Department of Entomology and Nematology, and UC Davis Comprehensive Cancer CenterUniversity of California DavisDavisUSA
  2. 2.Institute of Inorganic and Analytical ChemistryUniversity of MünsterMünsterGermany

Personalised recommendations